UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Link zum Volltext

Verfügbarkeit prüfen

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Clinical cancer research, 2008-12, Vol.14 (23), p.7884-7895

2008

Link zum Volltext

Verfügbarkeit prüfen

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Link zum Volltext

Verfügbarkeit prüfen

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Clinical cancer research, 2010-11, Vol.16 (22), p.5591-5602

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1597-1606

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Clinical cancer research, 2011, Vol.17 (1), p.193-200

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Cancer, 2010-02, Vol.116 (S4), p.1013-1017

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2002-07, Vol.8 (7), p.2142-2148

2002

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

Investigational new drugs, 2011-06, Vol.29 (3), p.481-488

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Investigational new drugs, 2011-02, Vol.29 (1), p.167-174

2011

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Clinical cancer research, 2004-10, Vol.10 (19), p.6512-6521

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Investigational new drugs, 2007-08, Vol.25 (4), p.359-367

2007

Link zum Volltext

Verfügbarkeit prüfen

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Breast cancer research : BCR, 2003-01, Vol.5 (3), p.154-159, Article 154

2003

Link zum Volltext

Verfügbarkeit prüfen

Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

The oncologist (Dayton, Ohio), 2002-01, Vol.7 (4), p.324

Rowinsky, Eric K

2002

Link zum Volltext

Verfügbarkeit prüfen

Therapeutics targeting signal transduction for patients with colorectal carcinoma

British medical bulletin, 2002-01, Vol.64 (1), p.227-254

2002

Link zum Volltext

Verfügbarkeit prüfen

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model

Cancer research (Chicago, Ill.), 1999-03, Vol.59 (5), p.1049-1053

1999

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies

Clinical cancer research, 2002-07, Vol.8 (7), p.2157-2166

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma

Investigational new drugs, 2001-02, Vol.19 (1), p.69-76

2001

Link zum Volltext

Verfügbarkeit prüfen

Novel agents in the treatment of lung cancer: Conference summary statement

Clinical cancer research, 2004-06, Vol.10 (12), p.4199s-4204s

2004

Link zum Volltext

Verfügbarkeit prüfen

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs

Clinical lung cancer, 2004-12, Vol.6 Suppl 1, p.S35-S42

2004

Link zum Volltext

Verfügbarkeit prüfen

Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer

Clinical colorectal cancer, 2004-07, Vol.4 (2), p.107-123

2004

Link zum Volltext

Verfügbarkeit prüfen

New antimitotic agents

Clinical advances in hematology & oncology, 2004-10, Vol.2 (10), p.636

Rowinsky, Eric

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

ThemaAntineoplastic Agents - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(37)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Oncology
(26)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Aged
(19)
Antineoplastic Agents
(19)
Female
(19)
Male
(19)
Middle Aged
(19)
Adult
(18)
Pharmacology. Drug Treatments
(17)
Chemotherapy
(15)
Antineoplastic Agents - Adverse Effects
(14)
Neoplasms - Drug Therapy
(12)
Tumors
(11)
Antibodies, Monoclonal - Therapeutic Use
(10)
Treatment Outcome
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

Therapeutics targeting signal transduction for patients with colorectal carcinoma

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model

A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies

Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma

Novel agents in the treatment of lung cancer: Conference summary statement

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs

Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer

New antimitotic agents

Aktive Filter

Suchergebnisse filtern